Search clinical trials for: AZD6765

Total 10 results

AstraZeneca

Completed

Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration (AZD6765)

Major Depressive Disorder

United Kingdom
AstraZeneca

Terminated

A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765 (AZD6765 EEG)

Healthy

France
AstraZeneca

Completed

A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels

Healthy

United States
AstraZeneca

Completed

AZD6765 for Treatment Resistant Depression

Depression

United States
AstraZeneca
National Institute of Mental Health (NIMH)

Completed

This is a Study to Determine the Antidepressant Effects of AZD6765

Treatment Resistant Major Depressive Disorder

United States
AstraZeneca

Withdrawn

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

Healthy

United States
AstraZeneca

Completed

AZD6765 Severe Major Depressive Disorder (MDD) IV

Major Depressive Disorder

United States
AstraZeneca

Completed

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects (JSAD/JMAD)

Healthy

United States
AstraZeneca
University of Oxford; University of Manchester

Completed

Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

Depression

United Kingdom
AstraZeneca

Completed

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

Major Depressive Disorder

United States, South Africa, Chile, Slovakia

3

Subscribe